Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2017: 3.556

CiteScore 2017: 2.34

SCImago Journal Rank (SJR) 2017: 1.114
Source Normalized Impact per Paper (SNIP) 2017: 1.188

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 50, Issue 10

Issues

Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation

Pascal J. Molenaar
  • Hematological Clinical Chemistry Laboratory, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Jasper Dinkelaar
  • Hematological Clinical Chemistry Laboratory, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Anja Leyte
  • Corresponding author
  • Hematological Clinical Chemistry Laboratory, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2012-03-30 | DOI: https://doi.org/10.1515/cclm-2012-0055

Abstract

Background: Rivaroxaban, a direct Xa inhibitor, is one of the new oral antithrombotic agents for which laboratory monitoring is thought to be unnecessary in most cases due to predictable pharmacokinetics. Circumstances are conceivable, however, in which reliable laboratory testing of Rivaroxaban is desirable. The aim of the present in vitro study was to investigate and compare the analytical and practical use of Rivaroxaban monitoring with routine screening assays, thrombin generation and anti-Xa activity, in a clinical laboratory setting.

Methods: Rivaroxaban was added to nine normal donor plasmas and to a normal pooled plasma in concentrations up to 1000 μg/L. Prothrombin time (PT), activated partial thromboplastin time (APTT), endogenous thrombin potential (ETP) and anti-Xa activity were measured in all donor samples. Responsiveness to Rivaroxaban and imprecision of Rivaroxaban recovery were assessed.

Results: Low intra-, but high inter-individual imprecision was found for PT displaying a linear dose-response relationship. Imprecision was much lower when directly measuring anti-Xa activity. Responsiveness of ETP lag-time was high, but of total thrombin generation was low, illustrating that the main effect of Rivaroxaban Xa inhibition lies in delaying thrombin formation rather than in preventing it.

Conclusions: Despite a high inter-individual imprecision of the PT, this relatively fast and cost-friendly assay is sensitive to Rivaroxaban and integrates its effects on the global coagulant state of patients. Anti-Xa activity assays can be run to assess the actual Rivaroxaban concentration and in the future ETP could serve as a fine-tuned hemostatic balance indicator for patients using Rivaroxaban.

Keywords: anti-Xa activity; BAY-59-7939; coagulation assays; Rivaroxaban; thrombin generation

About the article

Corresponding author: Dr. Anja Leyte, Onze Lieve Vrouwe Gasthuis Department HKCL, Oosterparkstraat 9, 1091 AC, Amsterdam, The Netherlands Phone: +31 205993049, Fax: +31 205993150


Received: 2012-01-26

Accepted: 2012-03-08

Published Online: 2012-03-30

Published in Print: 2012-10-01


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 50, Issue 10, Pages 1799–1807, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2012-0055.

Export Citation

©2012 by Walter de Gruyter Berlin Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Jing Tao, Elena N. Bukanova, and Shamsuddin Akhtar
Journal of Intensive Care, 2018, Volume 6, Number 1
[2]
Teruhiro Sakaguchi, Hiroyuki Osanai, Yosuke Murase, Hideki Ishii, Yoshihito Nakashima, Hiroshi Asano, Susumu Suzuki, Mikito Takefuji, Yasuya Inden, Kazuyoshi Sakai, Toyoaki Murohara, and Masayoshi Ajioka
Journal of Cardiology, 2017, Volume 70, Number 3, Page 244
[3]
Hiroyuki Hamada, Shinichi Wada, Yohei Mima, Masahiro Yasaka, Takahiro Kuwashiro, and Yasushi Okada
Nosotchu, 2016, Volume 38, Number 6, Page 413
[4]
HY Choi, S Choi, YH Kim, and HS Lim
CPT: Pharmacometrics & Systems Pharmacology, 2016, Volume 5, Number 10, Page 532
[5]
F. Ratzinger, M. Lang, S. Belik, P. Jilma-Stohlawetz, K. G. Schmetterer, H. Haslacher, T. Perkmann, and P. Quehenberger
Thrombosis and Haemostasis, 2016, Volume 116, Number 2, Page 235
[6]
Brian J. Dale, Noel C. Chan, and John W. Eikelboom
British Journal of Haematology, 2016, Volume 172, Number 3, Page 315
[8]
D. R. J. Arachchillage, I. J. Mackie, M. Efthymiou, D. A. Isenberg, S. J. Machin, and H. Cohen
Journal of Thrombosis and Haemostasis, 2015, Volume 13, Number 7, Page 1264
[9]
Herm Brinkman
Thrombosis Journal, 2015, Volume 13, Number 1, Page 9
[10]
Eva Herzog, Franz Kaspereit, Wilfried Krege, Jochen Mueller-Cohrs, Baerbel Doerr, Peter Niebl, and Gerhard Dickneite
Thrombosis Research, 2015, Volume 135, Number 3, Page 554
[11]
D. M. Siegal and B. A. Konkle
Hematology, 2014, Volume 2014, Number 1, Page 334
[12]
M. Van Blerk, E. Bailleul, B. Chatelain, A. Demulder, K. Devreese, J. Douxfils, K. Jochmans, F. Mullier, W. Wijns, M. R. Soumali, W. Coucke, K. Vernelen, and P. Van de Walle
Thrombosis and Haemostasis, 2014, Volume 113, Number 1, Page 154
[13]
Adam Cuker, Deborah M. Siegal, Mark A. Crowther, and David A. Garcia
Journal of the American College of Cardiology, 2014, Volume 64, Number 11, Page 1128
[14]
Yoshihisa Nakano, Takahisa Kondo, Hiroyuki Osanai, Yosuke Murase, Yoshihito Nakashima, Hiroshi Asano, Masayoshi Ajioka, Kazuyoshi Sakai, Yasuya Inden, and Toyoaki Murohara
Journal of Cardiology, 2015, Volume 65, Number 3, Page 185
[15]
Dieter Adelmann, Marion Wiegele, Rudolf Karl Wohlgemuth, Stefan Koch, Sophie Frantal, Peter Quehenberger, Gisela Scharbert, Sibylle Kozek–Langenecker, and Eva Schaden
Thrombosis Research, 2014, Volume 134, Number 4, Page 918
[16]
Matthew L. Moorman, Joshua E. Nash, and Katie L. Stabi
Journal of Trauma and Acute Care Surgery, 2014, Volume 77, Number 3, Page 486
[17]
Antoni Martínez-Rubio, George Andrei Dan, and Juan Carlos Kaski
Expert Review of Cardiovascular Therapy, 2014, Volume 12, Number 8, Page 933
[18]
R. Herrmann, J. Thom, A. Wood, M. Phillips, S. Muhammad, and R. Baker
Thrombosis and Haemostasis, 2013, Volume 111, Number 5, Page 989
[19]
[20]
Saartje Bloemen, Marieke De Laat, Bas De Laat, Hendrik Coenraad Hemker, and Raed Al Dieri
Drug Development Research, 2013, Volume 74, Number 7, Page 406
[21]
J. Dinkelaar, P. J. Molenaar, M. Ninivaggi, B. de Laat, H. J. M. Brinkman, and A. Leyte
Journal of Thrombosis and Haemostasis, 2013, Volume 11, Number 6, Page 1111
[22]
T. Baglin
Journal of Thrombosis and Haemostasis, 2013, Volume 11, Page 122
[24]
C. Eby
International Journal of Laboratory Hematology, 2013, Volume 35, Number 3, Page 262

Comments (0)

Please log in or register to comment.
Log in